Hepatitis B surface antigen loss and kinetic in chronic hepatitis B patients during interferon alpha treatment: a hospital-based real-world data analysis

XIN Ying,HUANG Guangyu,WANG Yuming,WANG Kaifa
2024-01-01
Abstract:Abstract: Background: The sustained loss of hepatitis B surface antigen (HBsAg) is an important alternative marker for chronic hepatitis B (CHB) functional cure, but the predictor for HBsAg loss and kinetic of related viral serological patterns in these uncured patients undergone long-term pegylated interferon alpha treatment remains insufficient. Methods: Retrospective data on CHB patients who were admitted to our institutions from May 30, 2018, to January 30, 2023, were collected, which are mostly regular weekly data. A total of 382 patients were enrolled for follow-up analysis, including 232 immune-inactive stage patients and 150 immune-active stage patients, and 95 patients achieved functional cure. Binary logistic regression analysis and profile analysis were performed to explore predictive factors for HBsAg loss and describe the kinetic patterns of the HBsAg continuously positive (CP) patients. Results: Besides baseline HBsAg, age was also the predictor for HBsAg loss for immune-inactive stages patients, and the suggested cut-off baseline HBsAg were obtained. For CP patients, both two immune stage groups exhibited a gradually decreasing kinetic pattern in HBsAg, but there was a reversal kinetic pattern between two immune stage groups in alanine aminotransferase (ALT). The difference of HBsAg and ALT kinetic was mainly reflected in the first 24 weeks after treatment. Female and hepatitis B e antigen (HBeAg) positive patients had a faster HBsAg decline rate than male and HBeAg negative patients respectively. Conclusions: Clinical consequence of HBsAg conversion and kinetic are not only correlated with clinical course status, but also related to gender and HBeAg grouping (negative/positive).
What problem does this paper attempt to address?